Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 12/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | YAP1 | P46937 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6042351 | 0.95 | REN (0.46) | RENTACR1PRMT5YAP1JAK2 | |
| SCHEMBL6041532 | 0.92 | REN (0.47) | RENTACR1PRMT5YAP1 | |
| SCHEMBL6042241 | 0.90 | REN (0.49) | RENTACR1PRMT5YAP1JAK2 | |
| SCHEMBL6041545 | 0.90 | REN (0.47) | RENTACR1PRMT5YAP1JAK2 | |
| SCHEMBL7075188 | 0.89 | REN (0.44) | RENTACR1PRMT5YAP1JAK2 | |
| SCHEMBL7080920 | 0.89 | REN (0.55) | RENTACR1PRMT5YAP1 | |
| SCHEMBL2807737 | 0.86 | BACE1 (0.45) | RENTACR1PRMT5YAP1JAK2 | |
| SCHEMBL2807748 | 0.86 | REN (0.44) | RENTACR1PRMT5YAP1JAK2 | |
| SCHEMBL4872229 | 0.86 | REN (0.41) | RENTACR1PRMT5YAP1JAK2 | |
| SCHEMBL2807746 | 0.86 | REN (0.44) | RENTACR1PRMT5YAP1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | REN 1485/4885TACR1 508/4885PRMT5 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.